The product is disappearing into reorder rhythm: revenue is shifting from won-each-time to arriving-on-its-own, and the
The model's full reasoning — Q1 2017 call → NOWe need answer only YES or NO. Need analyze transcript. Question asks: Does management describe that a growing share of company's revenue now arrives without a new selling event (reorders, refills, renewals, repeat purchases, usage-driven billing, aftermarket, consumable pull-through, customers' own routines) AND that this self-arriving share has recently and visibly grown as proportion of business, with management grounding shift in observed current behavior and treating as changing quality of revenue? We need use only transcript. Need determine if management says this. The transcript is Ionis Pharmaceuticals Q1 2017. They discuss SPINRAZA sales royalties. SPINRAZA is a drug for SMA, administered intrathecally, ongoing treatment. Revenue from royalties on sales. Is that self-arriving? They mention SPINRAZA sales over $47 million in Q1, launch momentum, patient demand high, physicians motivated. They also mention tiered royalties, as sales grow, portion increases. But is there description of growing share of revenue arriving without new selling event? The company earns royalties from Biogen on SPINRAZA sales. That is commercial revenue. But is it "self-arriving" due to reorders/refills? SPINRAZA is chronic therapy, patients need ongoing doses. But management doesn't explicitly discuss reorder rates or repeat mechanism. They talk about launch, patient demand, sites, insurance coverage. They say "commercial revenue from SPINRAZA royalties" added. But no mention of "growing share of revenue now arrives without new selling event" or "recently and visibly grown as proportion". They do say "addition of commercial revenue is a reflection of evolution of our business" and "we're tiered royalties... as sales grow, our portion increases." But that's about royalty rate tiering, not self-arriving revenue. Also they have R&D revenue from partnerships. The question is specific: management describes that a growing share of revenue now arrives without a new selling event through reorders etc. In transcript, no such description. They mention SPINRAZA sales, but not that it's self-arriving or repeat. They mention "patient demand is high and physicians are motivated to prescribe" but that's not repeat mechanism. They mention "launch building momentum" but not installed base reordering. So answer NO. Need ensure no other part. They discuss volanesorsen, Akcea, etc. No.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| IRBT | iRobot Corporation | Q3 2021 | 2021-10-28 | D |
| TOUR | Tuniu Corporation | Q4 2017 | 2018-03-14 | D |
DUOT · Q4 2023 → YESThe question is about whether management describes a growing share of revenue arriving without a new selling event, through reorders, renewals, etc., and that this has recently and visibly grown as a ...
QTRX · Q3 2023 → YESThe question is about whether management describes a growing share of revenue arriving without a new selling event, like through reorders, consumables, etc., and that this share has recently grown.
CYBR · Q3 2021 → YESThe question is about whether management describes a growing share of revenue arriving without a new selling event, like through renewals, and that this has recently grown as a proportion.